Stryker Q2 Sales Rise To $6.59Bn As Cyberattack Recovery Takes Hold
Stryker's Q2 earnings showed strong recovery from a March cyberattack, with sales rising to $6.59bn and EPS of $3.30. The company narrowed full-year guidance upward and flagged robust second-half demand for capital and surgical robotics.
Medtech Insight - July 31, 2026

Dexcom Lifts Full-Year Guidance, Looks Ahead To Mid-2027 Medicare Coverage Target
Dexcom lifted its full-year revenue guidance to $5.18bn–$5.25bn after a broad-based Q2 beat, with executives pointing to US patient growth, new international tenders and a Medicare expansion timeline targeting mid-2027.
Medtech Insight - July 31, 2026

European Biotech: ‘Why Are We Trying To Catch Up? We Should Aim To Leapfrog’
Argenx chairman and former CEO Tim Van Hauwermeiren believes Europe is not being ambitious enough for its biopharma sector, which otherwise risks being left behind by the US and China.
Scrip - July 31, 2026

Can Torrent Challenge Novo’s Semaglutide Franchise In Brazil?
As the largest Indian major in Brazil, Torrent aims for double-digit semaglutide market share, though it will not be part of the first wave of launches in the country.
Scrip - July 31, 2026

US Recovery, Emerging Market Gains, EU Troubles: Key Takeaways from Haleon’s Q2
Growth in key emerging markets like China and India propelled Haleon's sales growth in Q2. While the green shoots of recovery appeared in the US, challenging market conditions in Europe held back the world's largest consumer health company.
HBW Insight - July 31, 2026

Novo Nordisk’s Push Beyond Obesity Falters On Phase III Heart Drug Miss
A Phase III heart outcomes miss for ziltivekimab knocked 6.4% off Novo Nordisk’s shares and left the company more dependent than ever on its obesity franchise.
Scrip - July 31, 2026

Krka Raises Investments As It Looks To Expand Capacity
After a strong start to the year, the Slovenian pharma giant has invested additional funds into building up its production capacity as it continues to lead as an international provider of generic medicines, launching seven new products in the second quarter in a bid to expand its portfolio.
Generics Bulletin - July 31, 2026

Celltrion’s Confidence Grows To Exceed Full-Year Guidance
Celltrion is targeting more than its KRW5.3tr ($3.7bn) full-year guidance after H1 2026 revenues grew 45% year-on-year, driven by its newer slate of biosimilars that now accounts for the majority of biologics sales.
Generics Bulletin - July 31, 2026

Polpharma Matches Alvotech On Vedolizumab, But Trails On Subcutaneous Scope
Polpharma Biologics has secured US and European review for intravenous biosimilar vedolizumab PB016, matching Alvotech’s regulatory reach but trailing its broader strategy, which also includes subcutaneous formulations.
Generics Bulletin - July 31, 2026

Prostate Cancer Therapy Switching: The 60-day Cliff And Why Pharma Needs A Holistic View
Senior Indegene executive discusses findings from a real-world data study covering about 35,000 US prostate cancer patients, including how treatment switching is often planned than reactive and why pharma may want to strengthen patient support, reimbursement navigation, and payer engagement.
Scrip - July 31, 2026

Scrip’s Guide To August 2026: Key Drug Approvals And ESC Data
August brings a busy approvals calendar, more big pharma earnings and the ESC cardiology congress. Decisions on an mRNA flu vaccine, narcolepsy, myeloma and FOP products are among those that matter most.
Scrip - July 31, 2026

UCB Raises FY 2026 Guidance After Strong First Half But Warns On H2 Profitability
Despite raising its 2026 outlook after a strong first half, UCB's warning of second-half profitability pressures overshadowed continued commercial boost from Bimzelx and its newer growth brands.
Scrip - July 31, 2026

The Future of Surgery Is Here: How Medtronic Is Trading Surgical Gut Instinct For Data
Real-time recordings of surgical procedures, combined with edge-level AI analysis, are allowing Medtronic to transform the culture of surgery.
In Vivo - July 31, 2026

Incannex Bets On Psychotherapy As The Missing Ingredient In Psychedelic Medicine
As President Trump's executive order on psychedelics reshapes the regulatory landscape, Incannex Healthcare says its insistence on guided psychotherapy – and a real-world clinic to prove the model works – gives it an edge rivals have ceded.
In Vivo - July 31, 2026